142 related articles for article (PubMed ID: 36930126)
21. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
[TBL] [Abstract][Full Text] [Related]
22. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study.
Urakawa R; Isomura ET; Matsunaga K; Kubota K; Ike M
BMC Infect Dis; 2022 Feb; 22(1):179. PubMed ID: 35197017
[TBL] [Abstract][Full Text] [Related]
23. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
24. Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital.
Valera-Rubio MM; Sierra-Torres MIM; Castillejo García RR; Cordero-Ramos JJ; López-Márquez MRM; Cruz-Salgado ÓO; Calleja-Hernández MÁM
Expert Rev Vaccines; 2022 Apr; 21(4):533-540. PubMed ID: 34986076
[TBL] [Abstract][Full Text] [Related]
25. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
Rahmat H; Leelavathi M; Wan Ismail WF
Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
[TBL] [Abstract][Full Text] [Related]
26. Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.
Yoshida M; Kobashi Y; Shimazu Y; Saito H; Yamamoto C; Kawamura T; Wakui M; Takahashi K; Ito N; Nishikawa Y; Zhao T; Tsubokura M
Eur J Pediatr; 2023 Jan; 182(1):123-133. PubMed ID: 36224435
[TBL] [Abstract][Full Text] [Related]
27. Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia.
Mallhi TH; Khan YH; Butt MH; Salman M; Tanveer N; Alotaibi NH; Alzarea AI; Alanazi AS
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557002
[TBL] [Abstract][Full Text] [Related]
28. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
Maruyama A; Sawa T; Teramukai S; Katoh N
J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
[TBL] [Abstract][Full Text] [Related]
29. Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination.
Park MJ; Choi YJ; Choi S
J Korean Med Sci; 2021 Jul; 36(27):e196. PubMed ID: 34254475
[TBL] [Abstract][Full Text] [Related]
30. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
31. Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine.
Mori M; Yokoyama A; Shichida A; Sasuga K; Maekawa T; Moriyama T
Sci Rep; 2023 Nov; 13(1):19328. PubMed ID: 37935801
[TBL] [Abstract][Full Text] [Related]
32. Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea.
Kwon Y; Hwang I; Ko M; Kim H; Kim S; Seo SY; Cho E; Lee YK
Epidemiol Health; 2023; 45():e2023006. PubMed ID: 37183320
[TBL] [Abstract][Full Text] [Related]
33. Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine.
Borroni E; Consonni D; Cugno M; Lombardi A; Mangioni D; Bono P; Oggioni M; Uceda Renteria S; Bordini L; Nava CD; Letzgus M; Gentiloni Silverj F; Castaldi S; Rognoni M; Cavallieri D'Oro L; Carugno M; Riboldi L; Ceriotti F; Bandera A; Gori A; Pesatori AC
Med Lav; 2021 Dec; 112(6):477-485. PubMed ID: 34939617
[TBL] [Abstract][Full Text] [Related]
34. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
[TBL] [Abstract][Full Text] [Related]
35. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
36. Adverse Events Following BNT162b2 mRNA COVID-19 Vaccine Immunization among Healthcare Workers in a Tertiary Hospital in Johor, Malaysia.
Tan AY; Chang CT; Yu YK; Low YX; Razali NFM; Tey SY; Lee SWH
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455258
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack FP; Thomas SJ; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Moreira ED; Zerbini C; Bailey R; Swanson KA; Roychoudhury S; Koury K; Li P; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
N Engl J Med; 2020 Dec; 383(27):2603-2615. PubMed ID: 33301246
[TBL] [Abstract][Full Text] [Related]
38. Side effects after COVID-19 vaccinations among residents of Poland.
Andrzejczak-Grządko S; Czudy Z; Donderska M
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
[TBL] [Abstract][Full Text] [Related]
39. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021.
Ossato A; Tessari R; Trabucchi C; Zuppini T; Realdon N; Marchesini F
Eur J Hosp Pharm; 2023 Jul; 30(4):e15. PubMed ID: 34315774
[TBL] [Abstract][Full Text] [Related]
40. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
